Hyaluronic Acid Injections

Hyaluronic acid is a naturally occurring substance found in synovial fluid and cartilage, where it gives the joint fluid its thick, viscoelastic quality and helps it lubricate and cushion the joint. In osteoarthritis, the amount and quality of hyaluronic acid in the synovial fluid are reduced, and the fluid becomes thinner and less protective. Viscosupplementation is the idea of injecting hyaluronic acid into the joint to restore these viscoelastic properties, and additional anti-inflammatory and cartilage-protecting effects have been proposed, although these are not established.

In practice, hyaluronic acid is given as an intra-articular injection using an aseptic technique, most commonly into the knee, and sometimes into other joints such as the hip, where image guidance is used. Preparations vary in their molecular size and in the regimen: some are given as a single injection, and others as a course of injections spaced over several weeks. The intended effect is a reduction in pain and an improvement in function that may be delayed in onset compared with a corticosteroid, and that some studies suggest may last for a period of months in those who respond. Whether this translates into a reliable, clinically meaningful benefit is the central question, and it is where the evidence becomes important.

The evidence for hyaluronic acid in osteoarthritis is mixed and, overall, weak. Trials of intra-articular hyaluronic acid for knee osteoarthritis have shown inconsistent results, and where a benefit is seen it tends to be small and its clinical importance uncertain. On this basis, current UK osteoarthritis guidance advises against offering intra-articular hyaluronan injections for osteoarthritis, noting a lack of convincing evidence of improved quality of life, function or pain, and a signal of possible harm in hip osteoarthritis. A major international rheumatology body similarly recommends against the routine use of hyaluronic acid for knee osteoarthritis.

Where, then, does hyaluronic acid sit in practice? The foundation of osteoarthritis management remains exercise, weight management where relevant, education and appropriate analgesia, and the usual injectable option for short-term symptom relief is an intra-articular corticosteroid rather than hyaluronic acid. Hyaluronic acid is not routine UK standard care; current UK guidance is not to offer intra-articular hyaluronan for osteoarthritis. Any decision to use it despite this would need a clearly documented rationale, an explicit discussion of the limited evidence, and appropriate local governance, rather than being offered as a routine fallback. For the SEM clinician advising an athlete, the honest message is that hyaluronic acid is not an evidence-based standard treatment for osteoarthritis, and that attention is better directed to the core measures that do help.

If hyaluronic acid is used, a few practical points matter. It is given as an intra-articular injection using an aseptic technique, either as a single injection or as a short course over several weeks depending on the preparation, and image guidance is used for deeper joints. Its adverse effects are usually mild and local: a reaction at the injection site and a transient flare of pain are the most common. A rare but recognised reaction is an acute pseudoseptic reaction, a sterile inflammatory response that causes a hot, swollen, painful joint that can mimic infection; if this occurs, the joint is urgently assessed and aspirated where indicated, and a pseudoseptic reaction is only accepted once septic arthritis has been excluded. Unlike a corticosteroid, hyaluronic acid is not itself prohibited in sport and is not on the World Anti-Doping Agency Prohibited List, so it does not itself create an anti-doping problem, although the exact product and any co-administered drug are still checked, and any injection in a competing athlete is documented.

The most useful thing to convey to an athlete is realistic expectation. Hyaluronic acid is sometimes marketed enthusiastically, but it is not a proven or standard treatment for osteoarthritis, and it is not a substitute for the core management that genuinely improves symptoms and function. It is reasonable to explain what it is, what the evidence shows, and why it is not routinely recommended, and then to focus the plan on exercise, load and weight management, analgesia where needed, and a corticosteroid injection if a short-term boost is required to support rehabilitation. This keeps decisions grounded in evidence while respecting the athlete's autonomy to understand all the options.

• •Hyaluronic acid (viscosupplementation) is a natural component of synovial fluid that is reduced in osteoarthritis; injecting it aims to restore the fluid's viscoelastic properties.
• •It is given as an intra-articular injection, most often into the knee, as a single injection or a short course over several weeks.
• •The evidence for benefit in osteoarthritis is limited and inconsistent, and any benefit is small.
• •Current UK osteoarthritis guidance advises not offering intra-articular hyaluronan for osteoarthritis, and a major rheumatology body recommends against its routine use for knee osteoarthritis.
• •Core osteoarthritis management is exercise, weight management and analgesia, and the usual injectable for short-term relief is an intra-articular corticosteroid, not hyaluronic acid.
• •Adverse effects are usually a local reaction or transient flare; a rare pseudoseptic reaction can mimic infection, so the joint is urgently assessed and septic arthritis excluded first. Hyaluronic acid is not itself prohibited in sport, though the exact product and any co-administered drug are still checked.